Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04778553 |
| Other study ID # |
ESX-iMOST-X1-3 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
October 19, 2020 |
| Est. completion date |
January 21, 2021 |
Study information
| Verified date |
February 2021 |
| Source |
Essenlix Corporation |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
This is a method comparison study for an in vitro diagnostic device. The device is a point of
care automated hematology analyzer which measures CBC parameters with a small drop of venous
or capillary, e.g., fingerstick blood. The study compared the CBC results from the test
device, the Essenlix iMOST X-1 to the predicate laboratory based Horiba Pentra 60C+ analyzer.
The CBC parameters were hemoglobin, White Blood Cells (WBC) and the WBC Differential for
Granulocytes, Neutrophils, Lymphocytes and Monocytes. The study subjects were patient donors
(age 18 and older) attending the hospital clinic from whom Informed Consent had been
received.
Description:
These studies demonstrate that the iMOST X-1 system yields equivalent results to the Horiba
predicate system when using either capillary and venous blood specimens. Furthermore, there
are three alternative methods of capillary blood sampling for the iMOST and all have direct
applicability to the iMOST system. As has been published in the peer reviewed literature,
different fingerstick sample collection methods yield slightly different CBC results,
specifically the WBC and the WBC Differential. The iMOST employs an integrated software
algorithm with which the use can employ site specific calibration constants to correctly
match the selected capillary blood specimen to the venous specimen for the WBC test results.
All three methods of blood collection are thus described in the "Instructions for Use".
